Log In
BCIQ
Print this Print this
 

ASLAN004, CSL334

  Manage Alerts
Collapse Summary General Information
Company CSL Ltd.
DescriptionHuman mAb against IL-13 receptor alpha 1 (IL-13RA1; IL-13Ra; CD213A1)
Molecular Target Interleukin-13 (IL-13) receptor alpha 1 (IL-13RA1) (IL-13Ra) (CD213A1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation
PartnerAslan Pharmaceuticals Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/19/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today